The role of natural killer cells in immunity against multiple myeloma.
about
Immune checkpoint blockade for hematologic malignancies: a reviewAntigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.Profile of elotuzumab and its potential in the treatment of multiple myelomaThe cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapyThe critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaMultiple solitary plasmacytoma with multifocal bone involvement. First clinical case report in a uraemic patient.Immunotherapeutic approaches to treat multiple myelomaPreclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionModulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds.A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.NK-92 cell, another ideal carrier for chimeric antigen receptor.Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.
P2860
Q33645590-70B1DE26-084C-4CC5-917E-4BA25CC53AC1Q35034803-F8F10E73-09D6-4E4A-A9B7-75BA0D74151CQ35628678-C9914B03-D089-40C1-86F3-6682FEE8D198Q35669068-F4AC391F-D3CA-4841-BFB9-2D405E5B5DD9Q36070261-6C8E6350-BADD-47AD-BFC1-224DDA31A590Q36436758-3702883F-D30B-4343-9EE9-251EC5CCBDF1Q37413162-18837D17-76E1-4702-895A-05AB69DDC79BQ37666309-85630FA4-44FB-4817-8D35-FFF4749AA3E5Q38109553-903CDED3-214F-4D12-B3A1-CF5AAC4B4164Q38171067-E606E036-482B-41FF-9040-F988A1837344Q38526452-042CDF23-1F5C-445E-9C8F-6BFB2F9EB8D0Q38708402-0E0762C0-4FB1-4EF3-81DF-16D274B95F5EQ38722015-2EE25231-14E5-424E-97B8-9A01F452CB95Q38954303-7AACEE12-343B-443D-A869-9DFA9952C15EQ39136762-8C370908-3C7E-4F62-A4F9-2F84A84687DAQ39168624-4A98E8D8-AE1A-4C4A-867C-8DD67DADBE98Q41620482-BF8B8748-DDDE-42F1-AF37-F954AAAB6826Q41895213-7A27DD70-171D-44B3-87B0-A1B17A9F49C9Q42106541-EFFF9E82-9A71-44AF-8958-A3D1C03E2D5FQ42609665-76F86D6B-59EE-430C-A50F-920C1C2E1985Q50027824-2D79AFE6-380B-45E9-943A-E2710316658AQ51325371-A6DE0D15-E8A9-4F07-98A0-72E5DA0A4F62Q52777089-452020F9-8258-4544-AE00-719FF93E67E7
P2860
The role of natural killer cells in immunity against multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of natural killer cells in immunity against multiple myeloma.
@en
The role of natural killer cells in immunity against multiple myeloma.
@nl
type
label
The role of natural killer cells in immunity against multiple myeloma.
@en
The role of natural killer cells in immunity against multiple myeloma.
@nl
prefLabel
The role of natural killer cells in immunity against multiple myeloma.
@en
The role of natural killer cells in immunity against multiple myeloma.
@nl
P2860
P1433
P1476
The role of natural killer cells in immunity against multiple myeloma.
@en
P2093
Don M Benson
James Godfrey
P2860
P304
P356
10.3109/10428194.2012.676175
P577
2012-04-19T00:00:00Z